| Literature DB >> 24598740 |
Natalia Ponomarenko1, Spyros D Chatziefthimiou2, Inna Kurkova1, Yuliana Mokrushina1, Yuliana Mokrushina1, Anastasiya Stepanova1, Ivan Smirnov1, Marat Avakyan1, Tatyana Bobik1, Azad Mamedov1, Vladimir Mitkevich3, Alexey Belogurov1, Olga S Fedorova4, Michael Dubina5, Andrey Golovin6, Victor Lamzin2, Alain Friboulet7, Alexander A Makarov3, Matthias Wilmanns2, Alexander Gabibov1.
Abstract
The engineering of catalytic function in antibodies requires precise information on their structure. Here, results are presented that show how the antibody domain structure affects its functionality. The previously designed organophosphate-metabolizing reactibody A17 has been re-engineered by replacing its constant κ light chain by the λ chain (A17λ), and the X-ray structure of A17λ has been determined at 1.95 Å resolution. It was found that compared with A17κ the active centre of A17λ is displaced, stabilized and made more rigid owing to interdomain interactions involving the CDR loops from the VL and VH domains. These VL/VH domains also have lower mobility, as deduced from the atomic displacement parameters of the crystal structure. The antibody elbow angle is decreased to 126° compared with 138° in A17κ. These structural differences account for the subtle changes in catalytic efficiency and thermodynamic parameters determined with two organophosphate ligands, as well as in the affinity for peptide substrates selected from a combinatorial cyclic peptide library, between the A17κ and A17λ variants. The data presented will be of interest and relevance to researchers dealing with the design of antibodies with tailor-made functions.Entities:
Keywords: A17 reactibody; antibodies
Mesh:
Substances:
Year: 2014 PMID: 24598740 PMCID: PMC3949517 DOI: 10.1107/S1399004713032446
Source DB: PubMed Journal: Acta Crystallogr D Biol Crystallogr ISSN: 0907-4449
Figure 1Chemical compounds and antibody chains used in this study. (a) R = H, p-nitrophenyl 8-methyl-8-azabicyclo[3.2.1]octylphenylphosphonate (phosphonate X); R = biotin, biotinylated phosphonate X (BtX). (b) O,O-Diethyl O-(4-nitrophenyl)phosphate (paraoxon). (c) Amino-acid sequences of A17 κ and λ light chains and the heavy chain. Residues are numbered using the Kabat system (superlinear) and sequential numbering (interlinear). Frameworks (FR1–FR4) are underlined; switch residues of the J segment are designated as FR4 according to Kabat; CDRs are coloured magenta; constant domains κCL, λCL and CH1 are coloured green, yellow and blue, respectively.
Data-collection and refinement statistics
| Data-collection statistics | |
| Source | MX beamline P14, PETRA III, EMBL/DESY |
| No. of images | 380 |
| Oscillation range () | 0.25 |
| Space group |
|
| Unit-cell parameters () |
|
| Wavelength () | 1.2234 |
| Resolution () | 25.01.95 (2.061.95) |
|
| 9.6 (85.4) |
|
| 10.4 (92.0) |
|
| 3.8 (33.9) |
| CC1/2 | 99.7 (79.3) |
|
| 15.6 (2.7) |
| Completeness (%) | 99.9 (100) |
| Multiplicity | 7.3 (7.3) |
| Estimated | 26.9 |
| Refinement statistics | |
| Resolution range () | 25.01.95 |
| No. of reflections used for | 39334/1971 |
|
| 20.5/25.5 |
| No. of atoms | |
| Protein | 3326 |
| Ligands | 12 |
| Solvent | 310 |
|
| |
| Protein | 24.8 |
| VH | 18.4 |
| CH | 34.6 |
| VL | 20.6 |
| CL | 26.1 |
| Ligands | 19.1 |
| Solvent | 27.8 |
| Root-mean-square deviations | |
| Bond lengths () | 0.01 |
| Bond angles () | 1.12 |
| Ramachandran plot, residues in | |
| Most favoured regions | 427 [96.8%] |
| Favoured regions | 20 [3.2%] |
| Disallowed regions | 0 |
Figure 2(a) The overall structure of the A17λ antibody. Heavy (VH/CH1) and light chains are shown in magenta and cyan, respectively. (b) The A17λ structure coloured according to the Cα atomic displacement parameters (ADP), with a colour transition from blue to red indicating increasing ADP values.
Figure 3(a) 2F o − F c electron-density map contoured at the 1.5σ level above the mean (0.4 e Å−3) showing the MES molecule, water 147 and the catalytic Tyr-L36. Heavy and light chains are shown in magenta and cyan, respectively. (b) An extended hydrogen-bonding pattern involving the MES molecule and five intact water molecules located close to the A17λ active centre (red dashed lines).
Figure 4(a) Interdomain interactions between the CDR loops of A17λ and interactions involving catalytic Tyr-L37. Protein residues involved in these interactions are shown in ball-and-stick representation, water molecules are shown as spheres and hydrogen-bond interactions are shown as blue dashed lines. Here and in (b) and (c), heavy and light chains are shown in magenta and cyan, respectively. Tyr-L33 and Ser-L35 belong to L-CDR1, Asp-L51 to L-CDR2, Trp-L92 and LeuL96 to L-CDR3, Tyr-H53 to H-CDR2, and Ser-H103, His-H104 and Asn-H105 to H-CDR3. (b) 2F o − F c electron-density map contoured at the 2σ level (0.5 e Å−3) above the mean for the CDR loop region of A17λ. (c) 2F o − F c electron-density map contoured at the 2σ level (0.5 e Å−3) above the mean for the CDR loop region of A17κ.
Figure 5(a) Superposition of the A17λ and A17κ variable domains. A17λ CDR loops are shown in magenta and A17κ CDR loops are shown in blue. The flip of the Trp-L92 side chain is indicated. (b) The flipping of Trp-L92 provides the enlargement of the hydrophobic pocket surface (Trp-L92–Phe-L100) and the formation of a kind of lid above the cavity entrance. The light chain of A17κ is shown in cyan and the heavy chain is shown in brown; the light chain of A17λ is shown in green and the heavy chain in shown in magenta.
Figure 6Structural superposition of the A17κ (blue) and A17λ (magenta) light chains on the VL domain. The Gly-L110 insertion in A17λ accounts for the change in the VL–CL orientation compared with that in A17κ.
Figure 7Elbow angles in A17 reactibody variants. A17κ-P is a phosphonylated variant.
Kinetic parameters for the interaction of phosphonate X with and variants of A17
| Phosphonate X | Paraoxon | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| A17 | 0.24 0.03 | (120 15) 106 | 2000 500 | 6.5 0.1 | 4.1 0.3 | 4.0 1.2 | 12.5 1.3 | 1.2 0.5 |
| A17 | 0.28 0.02 | (130 15) 106 | 2200 400 | 6.5 0.1 | 3.0 0.4 | 7.6 1.8 | 11.4 0.5 | 1.6 0.6 |
E a is the activation-energy parameter.
Stopped-flow kinetic parameters of the interaction of phosphonate X with and variants of A17
The errors indicated are 1 SD.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| A17 | (6.6 0.5) 106 | 460 35 | 46 7 | 150 20 | 530 90 | 130 30 |
| A17 | (17.5 0.8) 106 | 480 35 | 65 10 | 90 12 | 580 90 | 80 20 |
BiaCore affinity constants for interactions of A17 and A17 reactibodies with linear (50L and 54L) and cyclic (50C and 54C) peptides
|
|
|
|
| |
|---|---|---|---|---|
| A17 | 1.3 0.1 | 25.0 5.0 | 0.9 0.1 | 25.7 0.5 |
| A17 | 2.3 0.3 | 18.0 4.0 | 2.20 0.08 | 4.8 0.6 |